Previous analyses identified associations between the degree of B-cell depletion and achievement of renal response in lupus nephritis (LN). NOBILITY tested whether enhanced B-cell depletion with the type II anti-CD20 monoclonal antibody (mAb) obinutuzumab (OBI) could improve responses in LN.
